Keyphrases
Rituximab
100%
Systemic Lupus Erythematosus
100%
Rituximab Therapy
100%
Thrombotic Thrombocytopenic Purpura
100%
ADAMTS13 Protein
40%
Thrombocytopenia
20%
50 Years Old
20%
Prednisolone
20%
Autoantibodies
20%
Older Women
20%
B Cells
20%
Maintenance Therapy
20%
Newly Diagnosed
20%
Time-based
20%
Remission
20%
CD19+ B Cells
20%
Severe Renal Impairment
20%
Plasmapheresis
20%
Patient Serum
20%
Remission Induction
20%
Glucocorticoid Pulse Therapy
20%
Thrombospondin-1 (TSP-1)
20%
Production Mechanism
20%
Member 13
20%
ADAMTS13
20%
Disintegrin
20%
B Cell Depletion Therapy
20%
Autoimmune Hemolytic Anemia
20%
Metalloproteinases
20%
Immune Thrombocytopenic Purpura
20%
Medicine and Dentistry
Rituximab
100%
Systemic Lupus Erythematosus
100%
Thrombotic Thrombocytopenic Purpura
100%
B Cell
42%
Von Willebrand Factor Cleaving Proteinase
42%
Thrombocytopenia
14%
Glucocorticoid
14%
Prednisolone
14%
Autoantibodies
14%
Pulse Rate
14%
Maintenance Therapy
14%
Severe Renal Impairment
14%
Plasmapheresis
14%
Metalloproteinase
14%
Evans Syndrome
14%
Disintegrin
14%
Idiopathic Thrombocytopenic Purpura
14%
Thrombospondin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
100%
Rituximab
100%
Thrombotic Thrombocytopenic Purpura
100%
Von Willebrand Factor Cleaving Proteinase
42%
Remission
28%
Prednisolone
14%
Thrombocytopenia
14%
Metalloproteinase
14%
Autoantibodies
14%
Glucocorticoid
14%
Severe Renal Impairment
14%
Autoimmune Hemolytic Anemia
14%
Disintegrin
14%
Thrombospondin
14%
Idiopathic Thrombocytopenic Purpura
14%